The Pharma Data

OCTOBER 22, 2020

FDA Approves Veklury (remdesivir) for the Treatment of COVID-19. Food and Drug Administration (FDA) has approved the antiviral drug Veklury (remdesivir) for the treatment of patients with COVID-19 requiring hospitalization. The speed and rigor with which Veklury has been developed and approved in the U.S.

FDA Approval 52

FDA Approval Treatment FDA Hospitals 52

The Pharma Data

MAY 27, 2022

Novartis today announced the US Food and Drug Administration (FDA) has granted accelerated approval for Kymriah ® (tisagenlecleucel) for the treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy.

FDA Approval 52

FDA Approval Therapies FDA Treatment 52

New Drug Approvals

APRIL 2, 2025

1] [2] It was developed by Vertex Pharmaceuticals , [5] and was approved for medical use in the United States in January 2025. [2] 2] [6] Suzetrigine is the first medication to be approved by the US Food and Drug Administration (FDA) in this new class of pain management medicines. [2] Suzetrigine is taken by mouth. [1]

FDA 62

FDA Therapies Trials Treatment 62

The Pharma Data

MAY 17, 2021

The authority to change drug labels outside of considerations for new safety information “could encourage third parties, such as academic investigators, insurance companies, and cooperative trial groups, to initiate such changes,” they wrote. . Posted 17 May 2021 | By Jeff Craven .

Research 52

Research FDA Approval Drugs FDA 52

Policy Prescription

OCTOBER 3, 2023

Salant’s paper supports personal drug importation and legalizing the importation of prescription drugs for commercial use so that wholesale pharmacies, including companies like Amazon and Costco, could tap into the parallel importation markets of other countries. First, drug prices in the U.S. He points to “a mere 1.5%

Pharmacy 84

Pharmacy International FDA Approval Government 84

The Pharma Data

MAY 27, 2022

billion in Medicare funds in 2019 on drugs whose clinical benefits have yet to be confirmed by the Food and Drug Administration, a new study led by researchers from the Johns Hopkins Bloomberg School of Public Health suggests. The program provides drug approval based on what is known as a surrogate endpoint.

Clinical Trials 52

Clinical Trials Drugs FDA Government 52

Pharmaceutical Development Group

DECEMBER 19, 2021

Start Up and Generic Pharmaceutical Drug and Biologic Companies have high quality, affordable products that improve the quality of life for their patients. In a FDA Pre-Submission that leads to FDA Approval, more does not equal better and more does not equal relevance to a specific Pharmaceutical Drug or Biologic Product.

FDA Approval 52

FDA Approval FDA Clinical Trials Drug Development 52

Pharmaceutical Development Group

JANUARY 7, 2022

Start Up and Generic Pharmaceutical Drug and Biologic Companies have high quality, affordable products and biosimilars that improve the quality of life for their patients. Seamless application of Data Standards, Data Integrity, begins no later than DMPK Protocols and all other Data filed in the Drug History File and used in the CMC.

FDA 52

FDA FDA Approval Biosimilars Regulations 52

Common Sense for Drug Policy Blog

MAY 1, 2024

However, prescription drugs must be approved by the Food and Drug Administration (FDA). Although FDA has approved some drugs derived from or related to cannabis, marijuana itself is not an FDA-approved drug.

FDA Approval 52

FDA Approval FDA Compliance Production 52

New Drug Approvals

DECEMBER 19, 2022

FDA 12/1/2022, To treat adults with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation, Rezlidhia Olutasidenib , sold under the brand name Rezlidhia , is an anticancer medication used to treat relapsed or refractory acute myeloid leukemia. [1] 1] It is taken by mouth. [1] Hz, 1 H), 4.62−4.75

FDA Approval 52

FDA Approval FDA Treatment Pharmaceuticals 52

The Pharma Data

JANUARY 6, 2021

7, 2021 /PRNewswire/ — UNION therapeutics A/S ( UNION ) today announces that the US Food and Drug Administration (FDA) has approved an Investigational New Drug program (IND) for oral orismilast; a next generation PDE4-inhibitor for the treatment of plaque psoriasis in adults. HELLERUP, Denmark , Jan.

FDA Approval 52

FDA Approval FDA Clinical Development Clinical Research 52

New Drug Approvals

SEPTEMBER 8, 2024

1] Palopegteriparatide was approved for medical use in the European Union in November 2023, [2] and in the United States in August 2024. [1] 5] Study drug and conventional therapy were subsequently adjusted according to the albumin-corrected serum calcium levels. [5] Food and Drug Administration (FDA) (Press release).

FDA 62

FDA International Trials FDA Approval 62

The ChEMBL-og

JUNE 13, 2023

References to primary literature are indicated in the ACTIVITY_PROPERTIES table (TEXT_VALUE AND STANDARD_TEXT_VALUE fields).

FDA Approval 97

FDA Approval Pharmacokinetics International Production 97

NIH Director's Blog: Drug Development

JUNE 14, 2016

Several years ago, the Food and Drug Administration (FDA) recommended that drug developers take special care to show that potential drugs to treat diabetes don’t adversely affect the cardiovascular system [1]. In fact, the evidence suggests that such drugs might even offer some protection against heart disease.

Drugs 52

Drugs Disease Drug Development Clinical Trials 52

New Drug Approvals

SEPTEMBER 6, 2024

2 , 3 Lazertinib was first approved in South Korea on January 18, 2021, for the treatment of EGFR T790M mutation-positive non-small cell lung cancer (NSCLC) with EGFR mutations. 1 It was approved by the FDA on August 19, 2024. 2] Names Lazertinib is the international nonproprietary name. [7] 20 August 2024. PMC 8217052.

FDA Approval 48

FDA Approval FDA International Treatment 48

FDA Law Blog: Biosimilars

JANUARY 18, 2024

Palmer — A new lawsuit against FDA is the latest happening in the veterinary drugs space and, by extension, FDA’s Center for Veterinary Medicine (CVM). District Court challenging FDA’s plan to remove their products from the market. Specifically, FDA is looking to remove a drug called carbadox from the market.

FDA 59

FDA FDA Approval International Production 59

The Pharma Data

JANUARY 19, 2021

or (973) 890-8355 (International), conference ID 1580376. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to eight FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories.

FDA Approval 52

FDA Approval Laboratories Disease Pharmaceuticals 52

The Pharma Data

NOVEMBER 30, 2020

or (973) 890-8355 (International), conference ID 7442859. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to eight FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories.

FDA Approval 52

FDA Approval Laboratories Disease Pharmaceuticals 52

New Drug Approvals

OCTOBER 24, 2023

Molecular Weight: 631.700 FDA APPROVED, To treat moderately to severely active ulcerative colitis in adults, 10/12/2023 Velsipity Etrasimod , sold under the brand name Velsipity , is a medication that is used for the treatment of ulcerative colitis (UC). [1] 1] [9] [10] Names Etrasimod is the international nonproprietary name. [11]

FDA 57

FDA FDA Approval International Pharmacokinetics 57

Drug Target Review

SEPTEMBER 19, 2023

The US FDA Modernisation Act 2.0., puts an end to the previous mandate that all drugs need to be tested on animals prior to human clinical trials. 3-5 Boston biotech, Emulate, established liver-on-chip device is designed to accurately measure liver toxicity and predict drug induced liver injury (DILI).

Animal Testing 98

Animal Testing Clinical Trials Pharmaceutical Companies FDA 98

New Drug Approvals

DECEMBER 24, 2023

2] [3] [4] [5] It was approved for medical use in the United States in December 2023. [6] 1] Society and culture Names Eplontersen is the international nonproprietary name. [9] S2CID 250989659. ^ “Eplontersen: FDA-Approved Drugs” U.S. Food and Drug Administration (FDA). 7 March 2023. .

Clinical Trials 62

Clinical Trials FDA Clinical Pharmacology FDA Approval 62

New Drug Approvals

SEPTEMBER 20, 2023

1] Motixafortide was approved for medical use in the United States in September 2023. [2] 4 Similar in mechanism to the previously approved plerixafor , motixafortide is an inhibitor of C-X-C Motif Chemokine Receptor 4 (CXCR4), a protein that helps to anchor stem cells to bone marrow matrix. 1] It is given by subcutaneous injection. [1]

FDA Approval 52

FDA Approval FDA International Clinical Trials 52

New Drug Approvals

APRIL 19, 2025

Landiolol 133242-30-5 ONO-1101 Ono 1101 WHO 7516 FDA APPROVED 11/22/2024, Rapiblyk , To treat supraventricular tachycardia C25H39N3O8 509.6 Mode of action The drug acts as an ultra-short-acting 1-selective blocking agent. Jump up to: a b “Novel Drug Approvals for 2024” U.S. 20 November 2023. AOP Health.

FDA 62

FDA Clinical Trials Treatment Trials 62

The Pharma Data

MAY 4, 2021

Pfizer plans to file for full FDA approval of Covid vaccine at the end of this month ( CNBC ). The FDA is set to authorize the Pfizer-BioNTech vaccine for those 12-15 years old by early next week. House Democrats ramp up pressure on drug prices ( Politico ). In Focus: International.

Vaccine 52

Vaccine FDA Approval FDA Licensing 52

The Pharma Data

APRIL 4, 2022

If approved, Actemra/RoActemra would be the first U.S. FDA approval is expected in the second half of this year. 7 Implementing an international differentiated pricing strategy specifically designed to address needs during this pandemic and improve affordability.7 today announced that the U.S. A decision on U.S.

Treatment 52

Treatment FDA Approval Clinical Trials FDA 52

Drug Target Review

MAY 27, 2024

How does the company see antibody-drug conjugates (ADCs) fitting into this approach? Antibody-drug conjugates have seen explosive growth in the last few years which has materialised with numerous clinical trials demonstrating meaningful improvements in survival. Examples include HER2-low and FOLR1.

Clinical Trials 59

Clinical Trials Science Molecular Biology Bioinformatics 59

PPD

AUGUST 5, 2024

Historically, the available drugs and U.S. Food and Drug Administration (FDA)-approved therapies for treating PAH were primarily vasodilators, designed to overcome the imbalance between vasoactive and vasodilator mediators and to restore endothelial cell function.

Clinical Trials 98

Clinical Trials Trials Clinical Research Disease 98

The Pharma Data

DECEMBER 1, 2020

Genesis is progressing both an internal drug pipeline, as well as select external partnerships, to create transformative therapies for patients. We are united in our view that drug discovery and development must raise its success rate. Feinberg, Ph.D., Genesis’ CEO and co-founder. “We

Engineering 40

Engineering FDA Approval Drugs Pharmaceuticals 40

Advarra

JUNE 20, 2023

of new cancer drugs tested in Phase I were likely to receive Food and Drug Administration (FDA) approval. Typical clinical development timelines for anticancer drugs average an estimated 6.7 This thereby proves the drug is also clinically meaningful or beneficial.

Trials 52

Trials Clinical Trials FDA Approval Therapies 52

The Pharma Data

DECEMBER 13, 2020

Food and Drug Administration (FDA) on Friday, December 11, 2020. During the meeting, the FDA provided encouraging feedback regarding the Phase 3 study of omidubicel pertaining to the pre-specified primary and secondary endpoints. Food and Drug Administration or any other health authority. About GDA-201.

Licensing 52

Licensing Licensing Clinical Trials FDA 52

The Pharma Data

JANUARY 5, 2021

Prader-Willi syndrome (“PWS”) will be the initial indication, which has been granted Orphan Drug and Fast Track Designation by the FDA. Food and Drug Administration (“FDA”). Canada) or (346) 406-0961 (international); conference ID: 9156145. We look forward to supporting Radius through our U.S.

Disease 52

Disease FDA Approval Clinical Trials Trials 52

The Premier Consulting Blog

NOVEMBER 12, 2023

This feedback prompted the FDA to release a second paper in 2021 titled “ Artificial Intelligence/Machine Learning (AI.ML)-Based Software as a Medical Device (SaMD) Action Plan ,” which outlined the agency’s five-pillar approach to regulating AI/ML. The number of drug submissions involving AI/ML has also increased.

FDA 52

FDA Drug Development Regulations FDA Approval 52

FDA Law Blog: Biosimilars

AUGUST 8, 2024

With apologies to Curtis Mayfield) By the close of the public comment period for the Drug Enforcement Administration’s (“DEA’s”) proposal to reschedule marijuana two weeks ago, the agency had received over 43,500 comments. This internal mandate may conflict with the state’s current allowance of marijuana for medical or recreational uses.

Regulations 59

Regulations Pharmacy Licensing Licensing 59

The Pharma Data

JANUARY 31, 2021

. The key component of Convergent’s PRRT prostate cancer therapy is its proprietary drug, CONV 01-?, If FDA approved, CONV 01-? would be the first antibody drug approved to direct a radioisotope into prostate cancer cells, and the first drug approved for the use of 225 Ac in cancer treatment. .

Small Molecule 40

Small Molecule FDA Approval Therapies Trials 40

The Pharma Data

MARCH 30, 2021

Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for atogepant, an investigational orally administered calcitonin gene-related peptide (CGRP) receptor antagonist (gepant), for the preventive treatment of migraine in adults who meet criteria for episodic migraine. UBRELVY® Indication.

Treatment 52

Treatment FDA Doctors Drugs 52

The Pharma Data

AUGUST 19, 2021

Lenacapavir is a breakthrough innovation that has the potential to be transformative for people with multi-drug resistant HIV, who have very limited treatment options,” said Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences. In June 2021, Gilead submitted a New Drug Application (NDA) for lenacapavir seeking U.S.

Marketing 52

Marketing Treatment FDA FDA Approval 52

The Pharma Data

AUGUST 19, 2021

Oral presentation at the International Association for the Study of Lung Cancer’s (IASLC) 2021 World Conference on Lung Cancer (WCLC) shows evidence that the bispecific mechanism of action for RYBREVANT TM can provide anti-tumor activity against either EGFR-mutated or MET-mutated non-small cell lung cancer.

Treatment 52

Treatment FDA Approval Pharmacokinetics FDA 52